173 related articles for article (PubMed ID: 36719280)
21. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
Alghamdi WA; Al-Shaer MH; Kipiani M; Barbakadze K; Mikiashvili L; Kempker RR; Peloquin CA
J Antimicrob Chemother; 2021 Mar; 76(4):1019-1024. PubMed ID: 33378452
[TBL] [Abstract][Full Text] [Related]
24. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
Harausz EP; Garcia-Prats AJ; Seddon JA; Schaaf HS; Hesseling AC; Achar J; Bernheimer J; Cruz AT; D'Ambrosio L; Detjen A; Graham SM; Hughes J; Jonckheere S; Marais BJ; Migliori GB; McKenna L; Skrahina A; Tadolini M; Wilson P; Furin J;
Am J Respir Crit Care Med; 2017 May; 195(10):1300-1310. PubMed ID: 27854508
[TBL] [Abstract][Full Text] [Related]
25. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
[TBL] [Abstract][Full Text] [Related]
26. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
Chesov D; Heyckendorf J; Alexandru S; Donica A; Chesov E; Reimann M; Crudu V; Botnaru V; Lange C
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942
[TBL] [Abstract][Full Text] [Related]
27. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
28. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
[TBL] [Abstract][Full Text] [Related]
29. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
[No Abstract] [Full Text] [Related]
30. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
31. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis.
Fu L; Weng T; Sun F; Zhang P; Li H; Li Y; Yang Q; Cai Y; Zhang X; Liang H; Chen X; Wang Z; Liu L; Zhang W; Deng G
Int J Infect Dis; 2021 Oct; 111():138-147. PubMed ID: 34454119
[TBL] [Abstract][Full Text] [Related]
32. Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.
Wang Q; Pang Y; Jing W; Liu Y; Wang N; Yin H; Zhang Q; Ye Z; Zhu M; Li F; Liu P; Wu T; Chen W; Wu W; Qin Z; Qiu C; Deng Q; Xu T; Wang J; Guo R; Du Y; Wang J; Huang H; Chen X; Chu N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378718
[TBL] [Abstract][Full Text] [Related]
33. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
34. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
35. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Li J; Yang G; Cai Q; Wang Y; Xu Y; Zhang R; Lang Y; Cai X
Int J Infect Dis; 2021 Sep; 110():179-186. PubMed ID: 34293490
[TBL] [Abstract][Full Text] [Related]
36. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
37. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Kunkel A; Cobelens FG; Cohen T
PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
[TBL] [Abstract][Full Text] [Related]
38. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Xu HB; Jiang RH; Xiao HP
Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
Dey T; Brigden G; Cox H; Shubber Z; Cooke G; Ford N
J Antimicrob Chemother; 2013 Feb; 68(2):284-93. PubMed ID: 23054996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
